Dog Mast Cell Tumour: Quality of Life and Welfare During Treatment

Mast cell tumours are among the most common canine cancers, and understanding the welfare implications of diagnosis, treatment, and end-of-life care is essential for dog owners and vets.

Key Facts

Mast cell tumours account for 16-21% of all canine skin tumours, making them one of the most frequently diagnosed
Grade I and II tumours often have good prognoses with surgery; Grade III tumours carry a much poorer outlook
Chemotherapy protocols for mast cell tumours include vinblastine and prednisolone - both have side effects
Nausea, fatigue, and immune suppression are common chemotherapy side effects affecting dog quality of life
The Canine Brief Pain Inventory is one tool used to assess comfort during mast cell tumour management
Palliative care, including corticosteroids and antihistamines, can maintain quality of life without aggressive treatment
End-of-life planning should begin early, while the dog is still comfortable, to avoid crisis decisions

Welfare Considerations

Dogs with mast cell tumours face welfare challenges at every stage: the stress of veterinary procedures, treatment side effects, and the physical discomfort of the tumour itself. Quality of life assessment should guide treatment decisions, not just tumour grade or owner preference. Evidence-based quality of life scales help owners and vets make consistent, welfare-focused decisions. Recognising when palliative care better serves the animal than curative treatment is a key welfare skill for both veterinary teams and dog owners.

What You Can Do

Discuss quality of life assessment tools with your vet when your dog is diagnosed with mast cell tumour
Ask about palliative care options if your dog is not a candidate for surgery or chemotherapy
Monitor your dog daily using a quality of life diary to track good and bad days
Ensure pain management is proactively addressed throughout diagnosis and treatment
Seek referral to a veterinary oncologist for Grade III tumours or complex cases